Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Mullally

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2010
NF1 inactivation revs up Ras in adult acute myelogenous leukemiaAnn Mullally, Benjamin L Ebert
Blood|August 26, 2025
Novel Strategies Targeting Mutant Calreticulin in Essential Thrombocythemia and MyelofibrosisGabriel S Salzman, Ann Mullally
Cold Spring Harbor Perspectives in Medicine|September 25, 2019
The Molecular Genetics of Myeloproliferative NeoplasmsAnna E Marneth, Ann Mullally
Blood|December 19, 2022
Biology and therapeutic targeting of molecular mechanisms in MPNsJoan How, Jacqueline S Garcia, Ann Mullally
Blood|September 29, 2019
Mutant calreticulin in myeloproliferative neoplasmsJoan How, Gabriela S Hobbs, Ann Mullally
Hematology/Oncology Clinics of North America|July 5, 2017
The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative NeoplasmsGabriela S Hobbs, Sarah Rozelle, Ann Mullally
Haematologica|December 5, 2024
Evolution of myeloproliferative neoplasms from normal blood stem cellsSahand Hormoz, Vijay G Sankaran, Ann Mullally
Blood Advances|April 29, 2020
Fedratinib in myelofibrosisAnn Mullally, John Hood, Claire Harrison, et al.
Cancers|August 27, 2020
Murine Models of MyelofibrosisSebastien Jacquelin, Frederike Kramer, Ann Mullally, et al.
Current Hematologic Malignancy Reports|January 8, 2025
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic ImplicationsMifra Faiz, Merle Riedemann, Jonas S Jutzi, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2010
NF1 inactivation revs up Ras in adult acute myelogenous leukemiaAnn Mullally, Benjamin L Ebert
Blood|August 26, 2025
Novel Strategies Targeting Mutant Calreticulin in Essential Thrombocythemia and MyelofibrosisGabriel S Salzman, Ann Mullally
Cold Spring Harbor Perspectives in Medicine|September 25, 2019
The Molecular Genetics of Myeloproliferative NeoplasmsAnna E Marneth, Ann Mullally
Blood|December 19, 2022
Biology and therapeutic targeting of molecular mechanisms in MPNsJoan How, Jacqueline S Garcia, Ann Mullally
Blood|September 29, 2019
Mutant calreticulin in myeloproliferative neoplasmsJoan How, Gabriela S Hobbs, Ann Mullally
Hematology/Oncology Clinics of North America|July 5, 2017
The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative NeoplasmsGabriela S Hobbs, Sarah Rozelle, Ann Mullally
Haematologica|December 5, 2024
Evolution of myeloproliferative neoplasms from normal blood stem cellsSahand Hormoz, Vijay G Sankaran, Ann Mullally
Blood Advances|April 29, 2020
Fedratinib in myelofibrosisAnn Mullally, John Hood, Claire Harrison, et al.
Cancers|August 27, 2020
Murine Models of MyelofibrosisSebastien Jacquelin, Frederike Kramer, Ann Mullally, et al.
Current Hematologic Malignancy Reports|January 8, 2025
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic ImplicationsMifra Faiz, Merle Riedemann, Jonas S Jutzi, et al.
Pageof 7